

**EMERGING INFECTIOUS DISEASE (EID) R&D MATRIX\***

		Basic research	Drugs	Vaccines	Biologics	Diagnostics	Vector control products	
<b>Arenaviral haemorrhagic fevers</b>	Lassa fever	✓	✓	✓	✓	✓	-	
	Multiple arenaviral haemorrhagic fevers (including Lassa fever)	✓	✓	✓	✓	✓	-	
	Other arenaviral R&D in combination with Lassa fever	✓	✓	✓	✓	✓	-	
<b>Bunyaviral diseases</b>	Crimean-Congo Haemorrhagic Fever (CCHF)	✓	✓	✓	✓	✓	✓	
	Rift Valley Fever (RVF)	✓	✓	✓	✓	✓	✓	
	Severe Fever with Thrombocytopenia Syndrome (SFTS)	✓	✓	✓	✓	✓	✓	
	Other bunyaviral R&D in combination with CCHF and/or RVF	✓	✓	✓	✓	✓	✓	
	Bunyaviral diseases other than CCHF, RVF and SFTS	✓	✓	✓	✓	✓	✓	
<b>Chikungunya</b>		✓	✓	✓	✓	✓	✓	
<b>Coronaviral diseases</b>	Middle East Respiratory Syndrome coronavirus (MERS)	✓	✓	✓	✓	✓	✓	
	Severe Acute Respiratory Syndrome (SARS)	✓	✓	✓	✓	✓	✓	
	Other coronaviral R&D in combination with MERS and/or SARS	✓	✓	✓	✓	✓	-	
	Highly pathogenic coronaviral diseases other than MERS and SARS	✓	✓	✓	✓	✓	-	
<b>Emergent non-polio enteroviruses (including EV71, D68)</b>		✓	✓	✓	✓	✓	-	
<b>Filoviral diseases</b>	Ebola	✓	✓	✓	✓	✓	✓	
	Marburg	✓	✓	✓	✓	✓	✓	
	Other filoviral R&D in combination with Ebola and/or Marburg	✓	✓	✓	✓	✓	-	
	Filoviral diseases other than Ebola and Marburg	✓	✓	✓	✓	✓	✓	
<b>Henipaviral diseases</b>	Nipah	✓	✓	✓	✓	✓	✓	
	Other henipaviral R&D including in combination with Nipah	✓	✓	✓	✓	✓	-	
	Henipaviral diseases other than Nipah	✓	✓	✓	✓	✓	✓	
<b>Zika</b>		✓	✓	✓	✓	✓	✓	
<b>Other investment applicable to more than one emerging infectious diseases or both neglected and emerging infectious diseases</b>								
<b>Platform technologies</b>						<b>Fundamental research</b>	<b>Broad-spectrum antivirals</b>	<b>Core funding of a multi-disease R&amp;D organisation</b>
General diagnostic platforms	Adjuvants and immunomodulators	Drug delivery technologies and devices	Vaccine delivery technologies and devices	Therapeutic platforms	Vaccine platforms			
✓	✓	✓	✓	✓	✓	✓	✓	

✓ denotes a category where a disease or product is included in the survey

\* The survey scope for emerging infectious diseases has not been defined using the same three-step filter used to determine the G-FINDER neglected disease survey scope. All relevant R&D activities for priority pathogens identified in the WHO R&D Blueprint review are considered in scope. The pathogens have been grouped by disease family for data collection purposes. See the [G-FINDER emerging infectious disease R&D scope document](#) for more detail.